Page 191 - 2020_01-Haematologica-web

Targeting mutant p53 in ALL
apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and over- expression of MDM2. Leukemia. 2008;22 (4):730-739.
24. Bykov VJ, Wiman KG. Mutant p53 reactiva- tion by small molecules makes its way to the clinic. FEBS Lett. 2014;588(16):2622-2627.
25. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7): 1323-1334.
26. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is trig- gered by p53 restoration in murine liver car- cinomas. Nature. 2007;445(7128):656-660.
27. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor func- tion to mutant p53 by a low-molecular- weight compound. Nat Med. 2002;8(3):282- 288.
28. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by cova- lent binding to the core domain. Cancer Cell. 2009;15(5):376-388.
29. Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9(5):439.
30. Tessoulin B, Descamps G, Moreau P, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood. 2014;124(10): 1626-1636.
31. Ali D, Mohammad DK, Mujahed H, et al. Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br J Haematol. 2016;174(1):117-126.
32. Mohell N, Alfredsson J, Fransson A, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6:e1794.
33. Peng X, Zhang MQ, Conserva F, et al. APR- 246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013;4:e881.
34. Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res. 2011;17(9):2830-2841.
35. Nahi H, Merup M, Lehmann S, et al. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene dele- tion. Br J Haematol. 2006;132(2):230-236.
36. Bykov VJ, Zache N, Stridh H, et al. PRIMA- 1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene. 2005;24 (21):3484-3491.
37. Izetti P, Hautefeuille A, Abujamra AL, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest New Drugs. 2014;32(5):783-794.
38. Liu DS, Read M, Cullinane C, et al. APR-246 potently inhibits tumour growth and over- comes chemoresistance in preclinical mod- els of oesophageal adenocarcinoma. Gut. 2015;64(10):1506-1516.
39. Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA- damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res. 2016;9(1):27.
40. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refrac- tory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30(29):3633-3639.
41. Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med.
2017;376(4):383-391.
42. Meyer LH, Eckhoff SM, Queudeville M, et
al. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is char- acterized by a gene signature involving sur- vival pathways. Cancer Cell. 2011;19(2): 206-217.
43. Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Human Mutat. 2016;37(9):865-876.
44. Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016;6:21.
45. Lisek K, Walerych D, Del Sal G. Mutant p53- Nrf2 axis regulates the proteasome machin- ery in cancer. Mol Cell Oncol. 2017;4(1): e1217967.
46. Liu DS, Duong CP, Haupt S, et al. Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumula- tion. Nat Commun. 2017;8:14844.
47. Haffo L, Lu J, Bykov VJN, et al. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Sci Rep. 2018;8(1):12671.
48. Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921-8946.
49. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth sup- pression distinguishes PRIMA-1 from known anticancer drugs: a statistical analy- sis of information in the National Cancer Institute database. Carcinogenesis. 2002;23 (12):2011-2018.
50. Synnott NC, Murray A, McGowan PM, et al. Mutant p53: a novel target for the treat- ment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234-246.
haematologica | 2020; 105(1)
181